Objective: To assess the antidepressant efficacy of S-adenosyl methionine (SAMe), a naturally occurring methyl donor, versus the selective serotonin reuptake inhibitor (SSRI) escitalopram and a placebo control; and to determine whether serum histamine or carnitine levels modified treatment response.
Introduction
Major Depressive Disorder (MDD) is a common, typically recurrent and disabling disorder. Complementary and Alternative Medicine (CAM) use is prevalent by sufferers of mood disorders, with data from a nationally representative sample in the USA of 2,055 people interviewed during [1997] [1998] revealing that 54% of those with severe depression reported using CAM during the previous 12 months (Kessler, Soukup et al. 2001 ).
S-adenosyl methionine (SAMe) is a naturally occurring substance synthesized from the amino acid L-methionine and adenosine triphosphate through the one-carbon cycle, a metabolic pathway that relies in part on adequate levels of folate and B12 (Spillmann and Fava, 1996; Papakostas et al, 2009 ). Routinely prescribed in Europe for nearly 30 years, SAMe has gained popularity in the U.S. following its release as an over-the-counter dietary supplement in 1998-99 (Mischoulon and Fava, 2002) .
SAMe has been proposed as a potential treatment for a number of medical conditions, particularly MDD (Spillmann and Fava, 1996) . Double-blind studies have demonstrated that parenteral or oral preparations of SAMe, compared with a number of standard tricyclic antidepressants (TCAs) such as clomipramine, amitriptyline, and imipramine, are generally equally effective, and tend to produce relatively fewer side effects (Bell et al, 1988; Delle Chiaie et al, 2002; Pancheri et al, 2002) . Recent work from our group has supported efficacy of SAMe as an augmentation agent in partial and non-responders to SSRIs and SNRIs (Alpert et al, 2004; Papakostas et al, 2010) One study thus far has compared the efficacy of SAMe versus both placebo and a standard selective serotonin reuptake inhibitor (SSRI) (Mischoulon et al, in press ).
These types of studies are important because, while SAMe may demonstrate equivalency with a standard antidepressant, an inactive comparator is necessary to rule out placebo effects. Likewise, if the natural product outperformed placebo, we need to know how this would compare to an active comparator. Finally, given the widespread use of SSRIs as first line antidepressants, many efficacy studies of novel putative antidepressants will use SSRIs as the standard comparator.
One proposed explanation for a number of psychiatric disorders that may align with the neurobiological action of SAMe is the histadelic model (Pfeiffer et al, 1970; Edelman, 2001) . This model suggests that mood and thought disorders may be caused, at least in some individuals, by elevated levels of histamine in the brain. Some studies have suggested that depression, bipolar disorder, schizophrenia, and drug abuse are associated with abnormal histamine levels, in some instances in as many as 20% of cases (Pfeiffer, 1988) . Elevated levels of histamine have been associated with severe depression, easy crying, insomnia, obsessive-compulsive ruminations, and suicidality (Pfeiffer, 1988) . Under-methylation and low serotonin have been implicated among the mechanisms involved in the presenting mood and thought abnormalities observed in histadelia (Pfeiffer, 1988; Edelman 2001) . Histadelic patients are not thought to respond well to conventional antidepressants or ECT. Investigation into the relationship between histadelia, depression, and response to treatment, could therefore prove valuable in the characterization and therapy of mood disorders.
Histamine is metabolized in part by SAMe, which methylates histamine's ring structure, thus forming N-methyl-histamine, a harmless metabolite (Pfeiffer, 1988; Edelman, 2001 ). Pfeiffer's model suggests that individuals with high levels of histamine would be especially likely to benefit from treatment with SAMe, and anecdotal data have supported this hypothesis. SAMe could potentially normalize histamine levels in the brain by methylating histamine. Conversely, depressed individuals with low or even normal histamine might not be expected to benefit as much from SAMe, assuming that histamine levels were playing a substantive role in their depression. Regardless, as SAMe modulates a range of neurochemical pathways, it still may be potentially effective in persons with low histamine.
Histadelia may also be relevant to mood disorder mechanisms because elevated histamine also results in low serotonin (Edelman, 2001) . It is therefore possible that administration of SSRI antidepressants may also have beneficial effects on histadelic individuals, and anecdotal evidence supports this idea. As it stands, there is limited systematic research on these issues, and data are limited to clinical anecdotes and studies with small subject samples.
Acetyl-L-carnitine (ALC) is an ester derivative of the trimethylated amino acid, Lcarnitine. ALC is synthesized in the human brain, liver, and kidney via the enzyme ALC-transferase. ALC is also available in the diet, in meat and dairy products. ALC facilitates uptake of acetyl CoA into the mitochondria during fatty acid oxidation, enhances acetylcholine production, and stimulates protein and membrane phospholipid synthesis (Indiveri et al, 2011) . Several studies, including some doubleblind, placebo-controlled trials, have shown that ALC may be of benefit in treating geriatric depression (Tempesta et al, 1987) , attention deficit disorder in children (Sarris et al, 2011) , and cognitive impairment associated with dementia (Hudson and Tabet, 2003) or alcoholism (Tempesta et al, 1990) . Our second aim was to analyze the relationship between histamine and carnitine levels and their response; and third, to determine if histamine or carnitine levels changed during the course of antidepressant treatment. We hypothesized that subjects with higher baseline levels of serum histamine or lower levels of carnitine would be more likely to improve with SAMe treatment compared to those with lower levels of histamine and higher levels of carnitine. We also predicted that SAMe treatment would be associated with lowering of serum histamine levels.
Methods

Overview and Eligibility Requirements
The data were provided from a clinical trial site (Massachusetts General Hospital: MGH) of a two-site parent study involving the acute 12-week controlled phase of a doubleblind, placebo-controlled administration of SAMe vs. escitalopram in 189 participants with MDD. This paper examines 144 subjects from the MGH site. The study was approved by the Partners Human Research Committee (IRB) and was registered on ClinicalTrials.Gov (NCT00101452).
The full methodology of the parent trial is detailed elsewhere (Mischoulon et al, in press ). Consenting outpatients with MDD were recruited from 4/13/05 to 12/22/09.
Inclusion criteria for eligibility into the study consisted of: participants with diagnosed MDD by the Structured Clinical Interview for DSM-IV Axis I Disorders -Patient Edition (SCID-I/P; First et al, 1995) , aged 18-80 years old, and a score of 25 or greater on the Inventory of Depressive Symptomatology -Clinician-Rated (IDS-C) (Rush et al, 1996) .
Patients must have also had Clinical Global Impression Improvement (CGI) scores > 2 (i.e. less than much or very much improved) from the screen to the baseline visit.
Exclusion criteria consisted of: pregnant women or women of child bearing potential who were not using a medically accepted means of contraception; patients with a range of psychiatric and medical disorders, or those on various medications; current use of other psychotropic drugs; previous moderate use of SAMe or escitolapram; ongoing psychotherapy; and multiple treatment failures.
Study Procedures
Following, if required, a two-week washout period for patients on antidepressants (fluoxetine required a four-week washout period), eligible and consenting subjects were randomly assigned to double-blind treatment with SAMe, escitalopram, or placebo for 12 weeks. Randomization was conducted via computerized random allocation by the research pharmacist, and the participants and assessors were both blinded to treatment. During the first week of the study and washout period, no medications were given. During the first six weeks of double-blind treatment, all patients were randomly assigned to one of three initial dosing regimens, with either SAMe tosylate disulfate 800mg twice per day (1600 mg/day divided into two doses, each dose containing 400mg of active SAMe ions: Group 1) or escitalopram (10 mg/day divided into two doses: Group 2); or double-dummy matching placebo (Group 3). A double-dummy design was employed whereby participants were given two bottles, with one bottle containing SAMe or SAMe placebo, and the other bottle containing escitalopram or escitalopram placebo. To maximize the probability of response, a dose increase was allowed for non-responders (patients with a <50% HAM-D-17 reduction from baseline) at week 6. Dose decreases to the previous level were allowed in cases of intolerable side effects from titration.
The primary outcome measure used to assess depression, was the 17-item Hamilton-D Scale (HAMD-17) (Hamilton, 1960) , while the Clinical Global Improvement-severity (CGI-S) (Guy, 1976 ) was used as a clinician-rated secondary outcome measure.
Assessments were conducted at Baseline and at weeks 1,2,4,6,8,10, and12. SAMe and matching placebo were supplied by Pharmavite, CA. Escitalopram and matching placebo were purchased from Forest Pharmaceuticals. SAMe tosylate disulfate and SAMe-placebo tablets were prepared to be identical in appearance and texture to ensure double-dummy, blind conditions. Pill counts were carried out at every visit to determine compliance. Subjects were compensated $25 for each completed visit.
In addition to normal testing procedures, study participants at MGH were asked to make two optional donations of 30ml of blood for the measurement of histamine and carnitine levels, collected at baseline and week 12. 
Statistical Analysis
Participants who met criteria for MDD and had a HAMD-17 score of >14 were analyzed as "intent-to-treat" using Last Observation Carried Forward (LOCF), in which all patients randomized to any of the three treatment arms had their data included in the analysis. The primary efficacy measure was the difference in change in HAMD-17 score across the three groups from baseline to week 12 endpoint. A repeated measures ANCOVA, using baseline HAMD-17 score as the covariate (Van Breukelen 2006), was conducted to assess differences between Group X Time, while a one-way ANOVA was used to assess any differences between groups across each time period. Adequate response was calculated at week 4, 8, and 12, and was defined as a 50 percent or greater decrease in HAMD-17 score. Remission was defined as a HAMD-17 score of 7 or less at endpoint. Interactions for response and remission rates were assessed via Chi-Square test with a Bonferroni correction for multiple comparisons. A linear regression analysis (Spearman's rho, due to sample size) was utilized to examine whether histamine and carnitine levels correlated with change on the HAMD-17 score, while an ANOVA was used to determine any differences between SAMe and escitalopram baseline levels and week 12 levels. All tests were 2-tailed, and significance (α) was set at 0.05. We calculated 
Results
One hundred and 144 eligible participants (44% female, mean age 47.6 +13.1) with diagnosed MDD underwent the washout screening phase. Fifty four participants completed the study: SAMe (n=18), escitalopram (n=20), and placebo (n=16), with no significant difference in attrition rates between groups. Upon study completion102 participants meeting inclusion criteria had data available for analysis SAMe (n=32), escitalopram (n=35), and placebo (n=35). Seventy four percent (74%) of the sample selfreported as Caucasian, 21% Black, 4% Hispanic, and 1% Asian. Eighty-eight percent (88%) had some college education or had graduated from college, 16% had high school level education, while 12% did not graduate from high school. Forty three percent (43%) of the sample had never been married, while 23% were currently in a relationship.
Thirty-nine percent (39%) were in some form of work, 26% were unemployed, 14% reported having a disability, 14% were retired, and 7% were either students or volunteers. No significant differences were found between the groups on any baseline characteristic.
Baseline HAMD-17 scores were 19.09 (+4.5), 20.83 (+4.6), and 20.63 (+4.4) for SAMe, escitalopram, and placebo, respectively, with no significant difference between groups (p=0.24). At the conclusion of the study at week 12, all treatments resulted in a significant reduction of HAMD-17 scores over time (F1,100 = 5.50, p=0.021). A mean (sd) reduction of 7.31 (5.96), 6.69 (5.70), and 4.00 (5.64) points on the HAMD-17 occurred for SAMe, escitolpram, and placebo, respectively. Repeated measures ANCOVA found a significant Group X Time interaction (F2,100 = 3.36, p=0.039: see Figure 1 ). Significant Group X Time differences were found from week 2 (p=0.002) through to endpoint week 12 (p=0.021), with the greatest differences occurring from week 2 to week 6 (p=0.002). A direct comparison between SAMe and placebo revealed a significant effect between baseline and endpoint (F1,65 = 5.89; p=0.018), with this effect occurring at every time point from week 1 (p=0.04) to week 12 (p=0.007), i.e. separation of SAMe from placebo occurred within a week of treatment initiation and was maintained throughout the course of treatment. SAMe was also found to be superior to escitalopram during weeks 2, 4, and 6, though this separation was lost from weeks 8-12 as the escitalopram arm improved further.
Direct comparison between escitalopram and placebo, however, did not reveal any significant Group X Time difference from baseline to endpoint (F1,68 = 2.44; p=0.12).
Likewise, no significant differences were seen for escitalopram versus placebo at any time-point. The effect size from baseline to endpoint HAM-D reduction was moderate to large for SAMe versus placebo (d=0.74), and moderate for escitalopram versus placebo (d=0.60).
Response rates (HAM-D >50% reduction) for treatments over time are detailed in Figure   2 . While no statistically significant differences were found on any time point, SAMe had a superior response rate over placebo over all time points and nearly reached significance at week 8 (X 2 1,61 = 3.39, p=0.066). At weeks 4, 8, and 12, respective response rates were 32%, 48%, and 45% for SAMe; 16%, 31%, and 31% for escitalopram; and 16%, 26%, and 26% for placebo. At week 12 endpoint, the remission rates (HAM-D< 7) were 34% for SAMe, 23% for escitalopram, and 6% for placebo. A significant difference was found between groups (X 2 2,102 =8.57; p=0.014). Individual comparisons in remission rates between placebo and treatments revealed a highly significantly difference for SAMe (p=0.003), and for escitalopram (p=0.023). On the secondary outcome, CGI-S was also significantly different between treatments and placebo from baseline to week 12 for SAMe (p=0.037), and for escitalopram (p=0.026).
Blood assays of a sub-sample of 20 participants with a measurable level of histamine, Furthermore, no significant differences were found between people who had a reduction of histamine from baseline to week 12, with response or remission rates (not shown).
Baseline carnitine levels for SAMe were 7.07ng/mL (+2.80), and for escitalopram 6.89ng/mL (+1.92.) (normal reference range 4.04-12.19 nmol/mL). Baseline levels were not found to have any relationship to response for SAMe (r= -0.14; p=0.60) or escitalopram (r= 0.08; p=0.78). Interventions were well tolerated with no significant adverse effects. Figures 2, 3 about here …………………………..
………………………… Insert
Discussion
Our results suggest that SAMe is significantly more effective than placebo in reducing depressed mood, while the SSRI comparator did not achieve this result. The effect size was moderate to large for SAMe indicating that a strong clinical effect occurred. This effect was maintained throughout the study, except that as the ANCOVA slope pattern depicts, the HAMD-17 scores rose slightly during the last two weeks for the SAMe group. In the escitalopram group, the ANCOVA slope revealed a steady reduction of depression, while as expected, the placebo group had a steady re-correction with a rise in depression from week 6.
The findings of this investigation need to be interpreted in the context of the parent clinical trial, which was essentially a failed study, in which all 3 treatment arms produced a significant clinical improvement, but neither active treatment separated from placebo. It should still be noted however that the MGH sample analyzed in this Strengths of this study include the use of an RCT design with an established SSRI comparator, and a relatively long treatment period. Of interest was that while results showed histamine levels were reduced by SAMe administration, baseline serum levels did not moderate response. This association cannot be discounted, however, because the sample size was underpowered due to one third of the sample either having no measurable histamine level, or not consenting for the blood tests. The regression slope (r of 0.34) for histamine in the SAMe group suggests that there is potential for participants with higher baseline levels of histamine to have a poorer response to treatment, which is the opposite of what we expected. It is possible that higher histamine levels are not so tractable to antidepressants, thus remaining an obstacle to effective response. Baseline carnitine levels also did not appear to moderate response to either treatment, though as discussed above, it would be premature to rule out this relationship. For instance, plasma levels of carnitine may not be indicative of levels of carnitine in the brain. Future research should explore histadelic effects in a much larger sample.
Even if there is no substantive relationship between SAMe and regulation of histamine and carnitine levels, there are various other neurochemical effects that may account for the therapeutic effect of SAMe, including enhanced methylation of catecholamines and increased serotonin turnover (Agnoli et al, 1977; Bottiglieri et al, 1986) , reuptake inhibition of norepinephrine (Cimino et al, 1984) , enhanced dopaminergic activity (Agnoli et al, 1977; Carney et al, 1986) , decreased prolactin secretion Fava et al, 1990) , increased conversion of phosphatidylethanolamine to phosphatidylcholine (Cimino et al, 1984) , and a potential decrease in the microviscosity of platelet membranes (Cohen et al, 1987) .
Limitations to this paper are recognized. First, because the sample size for the histamine and carnitine analyses was modest, we cannot confirm that these biomarkers are not salient to predicting response to treatment. Second, we may not be able to generalize these findings to other populations e.g. adolescent or geriatric. Third, because the data were analyzed from only one site of a two-site parent study, we cannot know what impact histamine and carnitine might have shown had the entire sample been analyzed for these biomarkers. Likewise, because the efficacy analysis of the MGH sample is post-hoc, its inconsistency with the findings of the sample as a whole needs to be interpreted with caution. In conclusion, our findings from this one site analysis provide encouraging evidence that SAMe is as an effective antidepressant agent, at least equivalent to the SSRI comparator escitalopram, and superior to placebo. Regardless, these results must be taken in context with the overall findings from the parent study. Preliminary evidence indicates that baseline histamine or carnitine levels do not necessarily moderate the effect of response to either SAMe or placebo. Further investigation of the impact of these biomarkers on antidepressant treatment response is warranted. Van Breukelen, 2006 . ANCOVA versus change from baseline: more power in randomiszed studies, more bias in nonrandomized studies. Journal of clinical epidemiology 9, 59. 
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